Antibiotic resistance is a major problem worldwide and there is an urgent need for new antibiotics to be developed. Potential new drugs are usually made in the lab which is complicated and time-consuming. An international team of scientists are using bacteria found naturally in the soil to produce new antibiotics in the fight against drug-resistant “Super-bugs” such as MRSA.
Led by Professor Tony Maxwell of the John Innes Centre (Norwich, UK) [1] and Professor Lutz Heide of the Pharmazeutisches Institut, Tübingen (Germany) [2], the team has developed ways of engineering harmless soil bacteria called Streptomyces to do the difficult chemistry for them. Streptomyces naturally make antibiotics to kill other bacteria in the soil. Unfortunately these don’t make very good drugs for use in humans because they are not very soluble in water and so cannot get into the bloodstream easily. The researchers have found a way to modify the bacteria to manufacture new varieties of these antibiotics that could be developed into more effective drugs. By studying variations of two natural antibiotics produced by Streptomyces, called novobiocin and clorobiocin, the scientists are determining which parts of the molecules are essential for their antibacterial activity. They hope that by varying other parts of the molecules they can design new antibiotics with better activity and fewer side effects.
Novobiocin and clorobiocin work by interfering with how DNA, the molecule that stores genetic information, is packed into the bacterial cell. The DNA in human cells is packed differently and so these cells are not affected by the antibiotics.
“This work is an excellent example of the European Union [3] at its best, combining the forces of seven labs from five different member states to carry out work that would not be possible by in lab working alone” said Tony Maxwell “We are very optimistic that we can make key discoveries about these antibiotics that will help them become vital weapons in our fight against MRSA and other bacterial infections”.
This exciting work is published this week in the journal Antimicrobial Agents and Chemotherapy [4] and will also be discussed at an event in Norwich as part of the BA Festival of Science in September 2006 [5].
1.The John Innes Centre (JIC), Norwich, UK is an independent, world-leading research centre in plant and microbial sciences. The JIC has over 800 staff and students. JIC carries out high quality fundamental, strategic and applied research to understand how plants and microbes work at the molecular, cellular and genetic levels. The JIC also trains scientists and students, collaborates with many other research laboratories and communicates its science to end-users and the general public. http://www.jic.ac.uk. The JIC is grant-aided by the Biotechnology and Biological Sciences Research Council.
2.Pharmazeutisches Institut, Auf der Morgenstelle 8, D-72076 Tübingen, Germany.
3.This work is published in the journal Antimicrobial Agents and Chemotherapy (Volume 50, issue 4) (Publishers: American Society for Microbiology).
4.This work was funded by a grant from the European Commission (Combigyrase LSHB-CT-2004-503466).
5.The BA (British Association for the Advancement of Science) Annual Festival of Science runs from 2nd-9th September 2006 in Norwich, and is the biggest public science event in the UK. It is expected to attract over 10,000 people from around the world with the theme of “People, Science and Society”.
Further information at the-ba.net/the-ba/Events/FestivalofScience
Peer reviewed publication and references
This work is published in the journal Antimicrobial Agents and Chemotherapy, 1 April 2006 (Volume 50, issue 4) (Publishers: American Society for Microbiology).